Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

, NVS

Novartis

$83.78

-0.29 (-0.34%)

09:08
08/29/18
08/29
09:08
08/29/18
09:08

Fly Intel: Pre-market Movers

HIGHER: Opiant Pharma (OPNT) up 78% after Emergent BioSolutions' (EBS) acquisition of Adapt Pharma. Cantor Fitzgerald analyst Brandon Folkes believes Emergent's acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market, such as Opiant... Glaukos (GKOS), up 37% after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. UP AFTER EARNINGS: Tilray (TLRY), up 14%... Shoe Carnival (SCVL), up 14%... Express (EXPR), up 4%. DOWN AFTER EARNINGS: Box (BOX), down 6.6%... Scansource (SCSC), down 1.5%... Dick's Sporting (DKS), down 9%. ALSO LOWER: Roku (ROKU), down 5.5% after The Information reported that Amazon.com (AMZN) is planning to launch a free video service for the estimated 48M people who use its Fire TV streaming video devices.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

NVS

Novartis

$83.78

-0.29 (-0.34%)

ROKU

Roku

$62.99

-1.15 (-1.79%)

AMZN

Amazon.com

$1,932.92

5.335 (0.28%)

OPNT

Opiant Pharmaceuticals

$15.61

-0.09 (-0.57%)

EBS

Emergent BioSolutions

$61.56

0.35 (0.57%)

TLRY

Tilray

$51.26

-2.24 (-4.19%)

SCVL

Shoe Carnival

$36.96

2.12 (6.09%)

EXPR

Express

$9.99

0.175 (1.78%)

BOX

Box

$26.61

0.62 (2.39%)

SCSC

Scansource

$43.15

0.65 (1.53%)

DKS

Dick's Sporting

$36.39

0.075 (0.21%)

  • 29

    Aug

  • 29

    Aug

  • 29

    Aug

  • 29

    Aug

  • 30

    Aug

  • 05

    Sep

  • 05

    Sep

  • 05

    Sep

  • 05

    Sep

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 27

    Sep

  • 01

    Oct

GKOS Glaukos
$44.79

-0.64 (-1.41%)

08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.
08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.
NVS Novartis
$83.78

-0.29 (-0.34%)

08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
ROKU Roku
$62.99

-1.15 (-1.79%)

08/28/18
LOOP
08/28/18
NO CHANGE
Target $52
LOOP
Hold
Roku price target raised to $52 from $43 at Loop Capital
Loop Capital analyst Alan Gould raised his price target on Roku to $52 to reflect his higher multiple estimate of 6.5-times his expected 2019 revenues, up from 5.5-times prior forecast. The analyst cites the company's continued market share capture of connected TVs, even though it faces a "substantial potential competition". Gould keeps a Hold rating on Roku, adding that there has recently been a "large amount of insider selling", even though he continues to expect the company to beat its quarterly estimates.
08/10/18
DADA
08/10/18
NO CHANGE
Target $44
DADA
Neutral
Roku price target raised to $44 from $32 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Roku to $44 after its Q2 results, with sales, EPS, and EBITDA all beating expectations. The analyst cites a 57% increase in usage - above his forecast of 50% - along with a 46% increase in active accounts and an average revenue per user increase of 40%. Forte also keeps his Neutral rating on Roku, noting that the current share price likely reflects its long-term growth prospects.
08/09/18
WBLR
08/09/18
NO CHANGE
WBLR
Outperform
Roku shares have additional 20% upside, says William Blair
William Blair analyst Ralph Schackart says that at the post-earnings share price of $51, Roku shares have additional upside around 20%. As the traditional TV ad market transitions in favor of over-the-top and streamed video, Roku is well positioned to take advantage, Schackart tells investors in a post-earnings research note. He believes the Roku Channel is making "significant progress" and keeps an Outperform rating on the shares.
08/29/18
KEYB
08/29/18
NO CHANGE
KEYB
KeyBanc sees plenty of room for both Amazon, Roku given TV advertising TAM size
KeyBanc analyst Evan Wingren notes The Information has reported that Amazon's (AMZN) IMBD subsidiary is working on a free, ad-supported streaming service, which sounds similar to what Roku (ROKU) is doing with The Roku Channel. The analyst says he has long expected this to be part of Amazon's advertising strategy and that it would be announced at some point. Given the size of the TV advertising TAM that has not yet transitioned to streaming, Wingren sees "plenty of room for both companies to operate this strategy" for the foreseeable future and be successful. Overall, the analyst believes Amazon has the potential to create a very compelling value proposition to advertisers with good execution.
AMZN Amazon.com
$1,932.92

5.335 (0.28%)

08/29/18
MSCO
08/29/18
NO CHANGE
Target $2500
MSCO
Overweight
Amazon price target raised to $2,500 from $1,850 at Morgan Stanley
Morgan Stanley analyst Brian Nowak expressed increasing confidence that Amazon's rapidly growing, high margin revenue streams - namely advertising, AWS, and subscriptions - will drive higher profitability and continue to push up consensus estimates. He has not made any changes to his estimates, but raised his price target on Amazon shares to $2,500 from $1,850 to reflect its improving business mix and his belief that the new target more accurately represents the company's long-term potential earnings power. In his new sum-of-the-parts model, Nowak values core retail at about $625B, values the AWS cloud business at roughly $375B, values Prime subscriber revenue at $100B and values the advertising business at $125B. He maintains an Overweight rating on Amazon shares, which closed yesterday at about $1,933 per share.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Walmart battle with Amazon set to escalate, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman believes Walmart's (WMT) battle with Amazon (AMZN) is about to intensify and he views its ability to counter Amazon's challenges as the key long-term debate on the stock. He believes Walmart shares are pricing in a continuation of 2-3% comps over the next few years with 40% e-commerce growth and improving e-commerce profitability, but he fears this may not be sustainable. He keeps an Equal Weight rating on Walmart shares, stating that to make him more bullish Walmart needs to show sustained top-line strength in both channels and to become more bearish he'd have to see U.S. EBIT margins contract more than he expects.
08/28/18
WBLR
08/28/18
NO CHANGE
WBLR
Outperform
Amazon upgrading printers to Kornit's new HD technology, says William Blair
Based on information from the Pennsylvania Department of Environmental Protection, William Blair analyst Brian Drab believes Amazon (AMZN) is upgrading Kornit printers that were already installed in its Pennsylvania textile printing facility to Kornit's new high definition print engine and also laying the groundwork to expand the facility from a maximum of 48 machines to 72 machines. In a research note titled "As Far as We Can Tell, Amazon Really Likes Kornit," Drab says Kornit's valuation is attractive given his expectation for about 20% revenue growth and margin driving greater than 30% earnings growth going forward. He points out that Amazon recently applied for two new air-quality permits and also submitted an application to expand capacity at its Pennsylvania facility from 48 printers to 72 printers. This is clearly a step toward upgrading the existing fleet of machines in the Pennsylvania facility to the HD technology Kornit introduced in early 2018, the analyst contends. He believes Amazon's e application for 72 printers is likely to be approved given it is essentially an addendum to previous permits. Drab estimates that an incremental 24 printers would likely generate about $10M in revenue for Kornit. He keeps an Outperform rating on the shares.
OPNT Opiant Pharmaceuticals
$15.61

-0.09 (-0.57%)

08/10/18
CANT
08/10/18
NO CHANGE
Target $32
CANT
Overweight
Cantor reiterates Overweight on Opiant ahead of pipeline readouts
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Opiant Pharmaceuticals with a $32 price target following the company's Q2 results. The analyst expect investors to begin to appreciate the market potential of Opiant's pipeline, "which should drive the stock higher." The company is developing treatments focused on multiple addictions as well a new product for opioid overdose, Folkes tells investors in a research note titled "Pipeline Readouts in '18 and '19 Make Us Even More Positive on OPNT Stock."
08/29/18
CANT
08/29/18
NO CHANGE
Target $32
CANT
Overweight
Cantor sees value in Opiant after Emergent acquires Adapt Pharma
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' (EBS) acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market. Opiant Pharmaceuticals (OPNT) is developing its own opioid overdose nasal spray, OPNT003, which could be of benefit in cases of synthetic opioid overdoses, such as with fentanyl, Folkes tells investors in a research note. He believes Opiant presents an attractive risk/reward at current share levels, "even if it captures only a portion of the growing market opioid overdose market." Folkes keeps an Overweight rating on the shares with a $32 price target.
06/11/18
CANT
06/11/18
INITIATION
Target $32
CANT
Overweight
Opiant Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Opiant Pharmaceuticals with an Overweight and $32 price target.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
EBS Emergent BioSolutions
$61.56

0.35 (0.57%)

08/10/18
WELS
08/10/18
NO CHANGE
Target $61
WELS
Market Perform
Emergent BioSolutions acquisition of PaxVax an 'excellent fit,' says Wells Fargo
After Emergent BioSolutions agreed to acquire PaxVax for $270M, Wells Fargo analyst David Maris said the transaction "sounds as though it is an excellent fit" and he is adding $70M in revenues for 2019 and assuming growth of 10% per year, though he thinks that could be conservative given the possible sales synergies. He also raised his price target on Emergent BioSolutions shares to $61 from $56, though he keeps a Market Perform rating on the shares.
06/13/18
06/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) initiated with a Sell at Berenberg. 2. Emergent BioSolutions (EBS) initiated with a Buy at Argus. 3. Nine Energy Services (NINE) initiated with a Strong Buy at Raymond James. 4. Can-Fite BioPharma (CANF) assumed with a Buy at H.C. Wainwright. 5. Control4 (CTRL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/18
CANT
08/29/18
NO CHANGE
Target $62
CANT
Overweight
Emergent acquisition should bridge guidance gap, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' acquisition of Adapt Pharma and its opioid overdose product, Narcan nasal spray, should help "bridge the Street's gap" from the current 2020 consensus revenue estimate of $830M to the company's guidance of $1B. The analyst keeps an Overweight rating on Emergent with a $62 price target.
TLRY Tilray
$51.26

-2.24 (-4.19%)

08/14/18
ROTH
08/14/18
INITIATION
Target $35
ROTH
Buy
Tilray initiated with a Buy at Roth Capital
Roth Capital analyst Charles Finnie started Tilray with a Buy rating and $35 price target. Although not the largest player, the company's unsurpassed product quality and cultivation expertise compare favorably to the leading Canadian Licensed Producers, he contends. The analyst expects revenues to grow at 40% plus annual rate over the next three to five years, with earnings growing considerably faster with expected operating margin expansion.
08/13/18
COWN
08/13/18
INITIATION
COWN
Outperform
Tilray initiated with an Outperform at Cowen
08/27/18
COWN
08/27/18
NO CHANGE
Target $34
COWN
Outperform
Tilray remains well positioned in cannabis market, says Cowen
Cowen analyst Vivien Azer believes Tilray remains well positioned to benefit from a legal recreational cannabis market in Canada. She noted it is an emerging industry and is subject to regulatory headwinds and she believes much work is needed for the industry to reach its full potential. Azer reiterated her Outperform rating on Tilray shares with a price target of $34. Tilray shares closed at $43.86 on Friday and in pre-market trading are up nearly 15% to $50.34.
SCVL Shoe Carnival
$36.96

2.12 (6.09%)

08/23/18
WEDB
08/23/18
NO CHANGE
Target $38
WEDB
Outperform
Shoe Carnival price target raised to $38 from $33 at Wedbush
Wedbush analyst Christopher Svezia raised his price target for Shoe Carnival to $38 from $33 given broad based strength in the quarter largely driven by athletic footwear and loyalty program activities. The analyst reiterates an Outperform rating on the shares.
07/19/18
SUSQ
07/19/18
DOWNGRADE
SUSQ
Neutral
Shoe Carnival downgraded to Neutral from Positive at Susquehanna
Susquehanna analyst Sam Poser downgraded Shoe Carnival to Neutral from Buy and maintained a $32 price target citing valuation following yesterday's positive move in shares. Poser is unsure why the stock popped to the degree that it did, up approximately 5%, saying he does not believe there is any activist activity, but does not discount the thought that there might have been an abrupt exit from a portion of the 27% short interest.
08/27/18
PIVT
08/27/18
NO CHANGE
Target $39
PIVT
Buy
Shoe Carnival price target raised to $39 from $31 at Pivotal Research
Pivotal Research analyst Mitch Kummetz raised his price target for Shoe Carnival to $39 ahead of tomorrow's Q2 results. The analyst believes the company had a "strong" quarter, driven by sandals early, favorable back-to-school trends late and a strong brand/product offering throughout the quarter. He models for same-store-sales at the high end of guidance and keeps a Buy rating on Shoe Carnival.
08/29/18
WEDB
08/29/18
NO CHANGE
Target $44
WEDB
Outperform
Shoe Carnival price target raised to $44 from $38 at Wedbush
Wedbush analyst Christopher Svezia raised his price target for Shoe Carnival to $44 from $38 saying it has momentum as Q2 results far exceeded Street expectations and the company raised the FY18 outlook, which is likely conservative. The analyst reiterates an Outperform rating on the shares.
EXPR Express
$9.99

0.175 (1.78%)

05/10/18
WEDB
05/10/18
INITIATION
WEDB
Neutral
Express initiated with a Neutral at Wedbush
Wedbush analyst Jennifer Redding initiated Express with a Neutral and $9 price target.
05/11/18
WEDB
05/11/18
INITIATION
Target $9
WEDB
Neutral
Express initiated with a Neutral on Q1 data at Wedbush
Wedbush analyst Jennifer Redding initiated Express with a Neutral and $9 price target. Redding said the promotional environment picked up in Q1 with increases in markdowns, indicating potential pressure to merchandise margins. The analyst said total company Average Price declined by 34% year-over-year, suggesting further AUR weakness.
05/11/18
05/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyson Foods (TSN) initiated with an Outperform at Bernstein. 2. Dexcom (DXCM) initiated with a Buy at BofA/Merrill. 3. Riot Blockchain (RIOT) initiated with a Buy at H.C. Wainwright. 4. American Eagle (AEO) initiated with an Outperform at Wedbush, while Abercrombie & Fitch (ANF) , Express (EXPR) initiated with a Neutral at Wedbush, and Lululemon (lulu) were initiated with a Neutral. 5. Lincoln National (LNC) reinstated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/18
05/31/18
NO CHANGE

Express sees Q2 EPS (2c)-2c, consensus 0c
Sees Q2 comparable revenue (-1%)-1%, consensus $477.29M, compared to a 10% decrease in 1Q17. .
BOX Box
$26.61

0.62 (2.39%)

05/31/18
05/31/18
DOWNGRADE
Target $25

Neutral
Box downgraded to Neutral on valuation, product timing at Rosenblatt
As previously reported, Rosenblatt downgraded Box to Neutral from Buy. Analyst Marshall Senk said recent share strength is likely attributed to enthusiasm around Box's AI driven product cycle, which he does not believe will impact results until Q4 of this year at the earliest. Given shares have passed through Senk's $25 price target and management reiterated on the call that this year is more back-end loaded, the analyst lowered his rating on shares.
05/31/18
ADAM
05/31/18
NO CHANGE
Target $30
ADAM
Buy
Box price target raised to $30 from $25 at Canaccord
Canaccord analyst Richard Davis raised his price target on Box to $30 from $25 following Q1 results. The analyst said there are enough good things going on at the company that the stock should work higher from here. He said he can see $30-$33 in the next 12-18 months based on its 2020 revenue estimates and he said he agrees with management that the line of sight to $1B in revenues is realistic. Davis reiterated his Buy rating on Box shares.
08/29/18
JMPS
08/29/18
NO CHANGE
Target $32
JMPS
Outperform
Box price target raised to $32 from $28 at JMP Securities
JMP Securities analyst Greg McDowell noted that Box reported second quarter revenue, non-GAAP EPS and billings that were above consensus forecasts. However, the stock slid in afterhours trading, which he attributes to a combination of Q3 billings growth, revenue and EPS guidance that were below consensus and what he sees as a "walk back" from a target of hitting a $1B revenue run-rate in the third quarter of FY21 to "not pinpointing" the quarter in which it will achieve that run-rate. His new $32 price target implies an unchanged revenue multiple applied to his newly introduced CY2020 revenue estimate. McDowell maintains an Outperform rating on Box shares.
07/20/18
FANA
07/20/18
INITIATION
Target $32
FANA
Overweight
Box initiated with an Overweight at First Analysis
First Analysis analyst Ken Wang started Box with an Overweight rating and $32 price target. The analyst sees growing new customer adoption of cloud-based solutions driving "sustained" 20%-plus revenue growth and an expanding margin profile for the company. He believes Box targets a "substantial" and growing market opportunity valued at approximately $45B.
SCSC Scansource
$43.15

0.65 (1.53%)

10/02/17
NRCS
10/02/17
DOWNGRADE
NRCS
Neutral
Scansource downgraded to Neutral from Buy at Northcoast
Northcoast analyst Keith Housom downgraded Scansource to Neutral citing valuation.
03/26/18
NRCS
03/26/18
UPGRADE
NRCS
Buy
Scansource upgraded to Buy from Neutral at Northcoast
DKS Dick's Sporting
$36.39

0.075 (0.21%)

08/15/18
OTRG
08/15/18
UPGRADE
OTRG
Positive
Dick's Sporting upgraded to Positive following checks at OTR Global
OTR Global upgraded Dick's Sporting to Positive from Mixed following checks that indicate Q2 sales were aided by favorable weather, increased customer interest in branded products, and price-matching programs.
08/15/18
OTRG
08/15/18
UPGRADE
OTRG
Positive
Dick's Sporting upgraded to Positive from Mixed at OTR Global
06/04/18
EVER
06/04/18
NO CHANGE
EVER
Dick's Sporting 3% Short Position closed in Model Portfolio at Evercore ISI
08/20/18
SUSQ
08/20/18
NO CHANGE
SUSQ
Positive
Nervousness not necessary ahead of footwear retailers' results, says Susquehanna
Susquehanna analyst Sam Poser noted investors are very nervous regarding earnings of footwear retailers, but he sees little to no reason for such nervousness. The analyst believes Dick's Sporting (DKS), Foot Locker (FL), and Hibbett Sports (HIBB) are well positioned heading into earnings. The analyst said product assortment is improving, inventory levels are as clean as they have been in years, and based on forward weeks of supply, all three are at historic lows. Poser believes the combination of better product and clean inventory will provide a revenue and margin tailwind in Q2 and beyond. Poser has a Positive rating on Dick's Sporting, Foot Locker, and Hibbett Sports shares.

TODAY'S FREE FLY STORIES

03:05
12/10/18
12/10
03:05
12/10/18
03:05
General news
FX Update: The Dollar and Sterling have come under general pressure »

FX Update: The Dollar…

YELP

Yelp

$34.60

0.19 (0.55%)

20:47
12/09/18
12/09
20:47
12/09/18
20:47
Periodicals
Yelp holder SQN to send letter pushing for business review, WSJ reports »

SQN Investors, a 4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

20:38
12/09/18
12/09
20:38
12/09/18
20:38
Periodicals
Gilead to hire Roche's Daniel O'Day as next CEO, WSJ reports »

Gilead Sciences (GILD)…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

UN

Unilever; also tag UL

$55.49

0.13 (0.23%)

, UL

Unilever; also tag UN

$54.04

0.17 (0.32%)

20:29
12/09/18
12/09
20:29
12/09/18
20:29
Downgrade
Unilever; also tag UL, Unilever; also tag UN rating change at JPMorgan »

Unilever downgraded to…

UN

Unilever; also tag UL

$55.49

0.13 (0.23%)

UL

Unilever; also tag UN

$54.04

0.17 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

JELD

Jeld-Wen

$16.85

-0.61 (-3.49%)

20:27
12/09/18
12/09
20:27
12/09/18
20:27
Downgrade
Jeld-Wen rating change at Goldman Sachs »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$42.60

0.07 (0.16%)

20:27
12/09/18
12/09
20:27
12/09/18
20:27
Upgrade
Fortune Brands rating change at Goldman Sachs »

Fortune Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANPDY

Anta Sports Products

$0.00

(0.00%)

19:46
12/09/18
12/09
19:46
12/09/18
19:46
Downgrade
Anta Sports Products rating change at Deutsche Bank »

Anta Sports Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KREF

KKR Real Estate Finance

$19.71

-0.095 (-0.48%)

19:42
12/09/18
12/09
19:42
12/09/18
19:42
Upgrade
KKR Real Estate Finance rating change at Keefe Bruyette »

KKR Real Estate upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$13.64

-0.11 (-0.80%)

19:34
12/09/18
12/09
19:34
12/09/18
19:34
Upgrade
Kratos Defense rating change at Goldman Sachs »

Kratos Defense upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$168.37

-6.37 (-3.65%)

, MSFT

Microsoft

$104.90

-4.27 (-3.91%)

19:30
12/09/18
12/09
19:30
12/09/18
19:30
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$168.37

-6.37 (-3.65%)

MSFT

Microsoft

$104.90

-4.27 (-3.91%)

DIS

Disney

$112.00

-1.385 (-1.22%)

PYPL

PayPal

$82.78

-3.07 (-3.58%)

AMAT

Applied Materials

$33.65

-1.04 (-3.00%)

CAT

Caterpillar

$123.54

-4.69 (-3.66%)

LEN

Lennar

$42.00

-0.43 (-1.01%)

NFLX

Netflix

$265.14

-17.66 (-6.24%)

PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

DB

Deutsche Bank

$8.74

-0.155 (-1.74%)

LITE

Lumentum

$41.92

-2.81 (-6.28%)

OCLR

Oclaro

$8.27

-0.165 (-1.96%)

FNSR

Finisar

$22.49

-0.53 (-2.30%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

CIEN

Ciena

$31.30

-0.95 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

  • 03

    Mar

LITE

Lumentum

$41.92

-2.81 (-6.28%)

, OCLR

Oclaro

$8.27

-0.165 (-1.96%)

18:16
12/09/18
12/09
18:16
12/09/18
18:16
Periodicals
Huawei CFO seeking bail, Reuters reports »

Huawei Chief Financial…

LITE

Lumentum

$41.92

-2.81 (-6.28%)

OCLR

Oclaro

$8.27

-0.165 (-1.96%)

FNSR

Finisar

$22.49

-0.53 (-2.30%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

INFN

Infinera

$4.38

-0.21 (-4.58%)

CIEN

Ciena

$31.30

-0.95 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

KERX

Keryx

$3.14

-0.035 (-1.10%)

, AKBA

Akebia

$8.52

-0.02 (-0.23%)

16:51
12/09/18
12/09
16:51
12/09/18
16:51
Conference/Events
Akebia to host special shareholder meeting »

Special Shareholder…

KERX

Keryx

$3.14

-0.035 (-1.10%)

AKBA

Akebia

$8.52

-0.02 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

AKBA

Akebia

$8.52

-0.02 (-0.23%)

, KERX

Keryx

$3.14

-0.035 (-1.10%)

16:49
12/09/18
12/09
16:49
12/09/18
16:49
Conference/Events
Keryx to host special shareholder meeting »

Special Shareholder…

AKBA

Akebia

$8.52

-0.02 (-0.23%)

KERX

Keryx

$3.14

-0.035 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

DVMT

Dell Technologies

$104.01

-1.51 (-1.43%)

16:35
12/09/18
12/09
16:35
12/09/18
16:35
Conference/Events
Dell Technologies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 07

    Mar

T

AT&T

$30.14

-0.38 (-1.25%)

, CMCSA

Comcast

$37.41

-0.46 (-1.21%)

16:34
12/09/18
12/09
16:34
12/09/18
16:34
Hot Stocks
Box Office Battle: 'Ralph Breaks the Internet' leads top office with $16.1M »

Disney's (DIS)…

T

AT&T

$30.14

-0.38 (-1.25%)

CMCSA

Comcast

$37.41

-0.46 (-1.21%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.19

-0.67 (-1.29%)

FOX

21st Century Fox

$48.99

-0.23 (-0.47%)

FOXA

21st Century Fox

$49.26

-0.21 (-0.42%)

LGF.A

Lionsgate

$17.58

0.28 (1.62%)

DIS

Disney

$112.00

-1.385 (-1.22%)

VIAB

Viacom

$29.91

-0.09 (-0.30%)

VIA

Viacom

$33.19

0.11 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

  • 20

    Mar

CNC

Centene

$133.28

-2.1 (-1.55%)

16:09
12/09/18
12/09
16:09
12/09/18
16:09
Conference/Events
Centene to hold a meeting »

2019 Financial Guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

FTI

TechnipFMC

$21.00

-0.69 (-3.18%)

16:00
12/09/18
12/09
16:00
12/09/18
16:00
Conference/Events
TechnipFMC to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$2.39

0.16 (7.17%)

15:56
12/09/18
12/09
15:56
12/09/18
15:56
Conference/Events
Catalyst Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

WPP

WPP

$52.11

-0.39 (-0.74%)

14:22
12/09/18
12/09
14:22
12/09/18
14:22
Conference/Events
WPP to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VISI

Volt Information Sciences

$2.64

-0.05 (-1.86%)

14:11
12/09/18
12/09
14:11
12/09/18
14:11
Conference/Events
Volt Information Sciences to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ARCT

Arcturus Therapeutics

$5.90

0.45 (8.26%)

13:52
12/09/18
12/09
13:52
12/09/18
13:52
Conference/Events
Arcturus Therapeutics to hold a conference call »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

STWD

Starwood Property

$22.34

-0.08 (-0.36%)

13:37
12/09/18
12/09
13:37
12/09/18
13:37
Conference/Events
Starwood Property to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

EZPW

Ezcorp

$8.74

-0.17 (-1.91%)

13:31
12/09/18
12/09
13:31
12/09/18
13:31
Conference/Events
Ezcorp to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NFLX

Netflix

$265.14

-17.66 (-6.24%)

, PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

13:20
12/09/18
12/09
13:20
12/09/18
13:20
Periodicals
Netflix, Palo Alto offer growth at a discount, Barron's says »

As stocks search for a…

NFLX

Netflix

$265.14

-17.66 (-6.24%)

PANW

Palo Alto Networks

$175.11

-6.73 (-3.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

DHR

Danaher

$101.94

-2.88 (-2.75%)

13:18
12/09/18
12/09
13:18
12/09/18
13:18
Conference/Events
Danaher to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.